Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors

IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11). The objective of this study was to evaluate the factors associated with interpatient variability in the pharmacokinetics and pharmacodynamics of IHL-305 in patients with advanced solid tumors. IHL-305 was administered intravenously...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Huali, Infante, Jeffrey R, Keedy, Vicki L, Jones, Suzanne F, Chan, Emily, Bendell, Johanna C, Lee, Wooin, Kirschbrown, Whitney P, Zamboni, Beth A, Ikeda, Satoshi, Kodaira, Hiroshi, Rothenberg, Mace L, Burris, Howard A, Zamboni, William C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334335/
https://www.ncbi.nlm.nih.gov/pubmed/25709442
http://dx.doi.org/10.2147/IJN.S62911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334335/
https://www.ncbi.nlm.nih.gov/pubmed/25709442
http://dx.doi.org/10.2147/IJN.S62911

Ejemplares similares